We dare to embrace bold approaches to expand the potential of science. Whether it’s exploring the intersection of T-cell biology and regenerative medicine, reducing excessive serotonin signaling contributing to disease or regulating inflammatory response in the lungs, we work with relentless follow-through to accelerate transformative medicines.
T-cells are fundamental to our body’s ability to fight infection and are a critical part of a functioning immune system. The Enzyvant T-cell platform is investigating the intersection of T-cell biology and regenerative medicine with the vision of bringing potentially life-changing therapies to patients who would otherwise have few or no options.
Learn more about the disease we have evaluated our T-cell platform in pediatric congenital athymia here
Learn more about our medicines created with our T-cell platform here
Peripherally Acting TPH Inhibitor
Serotonin helps maintain normal physiology, but its dysregulation can be a causative and persistent contributor to disease. Enzyvant is developing peripherally targeted inhibitors of serotonin biosynthesis to address the pathological effects of excessive serotonin signaling as potential treatments for a variety of conditions, including pulmonary arterial hypertension and idiopathic pulmonary fibrosis.
There are two separate pools of serotonin, one in the central nervous system (CNS) and the other in the periphery, which are separated by the blood-brain barrier. Enzyvant’s peripherally acting tryptophan hydroxylase (TPH) inhibitor was designed to be restricted to the peripheral circulation so it can selectively reduce serotonin in peripheral tissues and avoid impacting serotonin production in the brain.
Learn more about the disease we are evaluating our peripherally acting TPH inhibitor in, pulmonary arterial hypertension here
Learn more about our peripherally acting TPH inhibitor treatment in development for pulmonary arterial hypertension here
Interleukin-1 (IL-1) is a family of proteins that are involved in cell signaling and are believed to contribute to the development of many respiratory disorders. This family includes pro-inflammatory IL-1α and IL-1β and anti-inflammatory IL-1 receptor antagonist (IL-1Ra) – all of which have a role in the regulation of immune and inflammatory responses. While IL-1β is the primary driver of inflammation, Enzyvant’s IL-1Ra has an anti-inflammatory role that moderates the risk of excessive response.
Learn more about the diseases we are evaluating our recombinant IL-1Ra in, bronchiolitis obliterans syndrome and chemical lung injury
Learn more about our recombinant IL-1Ra treatment in development for bronchiolitis obliterans syndrome and chemical lung injury here